Skip to content

SAFE-HF - tranSlating heArt Failure guidElines into practice in a Nurse Practitioner primary care service

SAFE-HF - tranSlating heArt Failure guidElines into practice: a RCT evaluating rehospitalisations and mortality in a Nurse Practitioner primary care service

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12623001244695
Acronym
SAFE-HF
Enrollment
1200
Registered
2023-12-01
Start date
2024-01-10
Completion date
2025-01-10
Last updated
2023-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Current management of HF patients post-discharge is sub-optimal and patients are not receiving the full benefits of evidence-based care simply due to inaccessibility to a heart failure specialist team. The aim of this project is to assess implementation and effectiveness of a HF nurse practitioner primary care service. The HF nurse practitioner service can be integrated within primary care and will reduce hospitalisations and mortality.

Interventions

In addition to usual care, the patient will be seen face-to-face with a heart failure nurse practitioner in their local GP primary care practice. They will be seen weekly for 12 weeks commencing in the first week post-discharge. The purpose of the review by the heart failure nurse practitioner is to prescribe and titrate medications (such as beta-blockers, angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), angiotensin receptor neprilsyn inhibitor (ARNI), minera

In addition to usual care, the patient will be seen face-to-face with a heart failure nurse practitioner in their local GP primary care practice. They will be seen weekly for 12 weeks commencing in the first week post-discharge. The purpose of the review by the heart failure nurse practitioner is to prescribe and titrate medications (such as beta-blockers, angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), angiotensin receptor neprilsyn inhibitor (ARNI), mineralocorticoid receptor antagonist (MRA), sodium-glucose cotransporter 2 inhibitor (SGLT2i) and provide education about heart failure based on the Heart Foundation Heart Failure patient resource. Education topics include: what is heart failure, self-management of heart failure at home and lifestyle modifications. The education sessions will be face-to-face utilising the Heart Foundation resource and their education videos. The consultation review protocol is designed specifically for this study Each consultation will take 30 minutes and collect data about the treatment and management plans implemented during the consultations.

Sponsors

Deakin University
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Open (masking not used)

Eligibility

Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Patients hospitalised with heart failure and being discharged home, confirmed diagnosis of heart failure based on echocardiography, aged 18 years and over, living within the catchment area of participating health services, and not receiving palliative care.

Exclusion criteria

Patients discharged to an aged care facility or palliative care or patients not residing in the catchment area of their local health service

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026